Travellaggio / Shutterstock.com
12 August 2020AmericasSarah Morgan
McDermott hires Boston pair from Polsinelli
McDermott Will & Emery has strengthened its IP practice in Boston with the addition of Michael Siekman and Jenny Chen as partners.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
article
3 March 2020 April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.
Americas
6 August 2020 The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
Editor's picks
Editor's picks
article
3 March 2020 April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.
Americas
6 August 2020 The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
article
3 March 2020 April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.
Americas
6 August 2020 The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.